In contrast, as leukaemia stem cells in de novo AML samples are highly dependent on amino acid metabolism to drive oxidative phosphorylation, combining BCL-2 inhibitor venetoclax with DNMT inhibitor azacytidine in these cells was shown to reduce oxidative phosphorylation by decreasing the usage of the amino acid metabolic pathway [233,234]. Here, DNMT1 is linked to acute myeloid leukemia.